Navigation Links
Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses
Date:1/24/2008

ARLINGTON, Va., Jan. 25 /PRNewswire-USNewswire/ -- A report released today by The Cornucopia Institute presents research indicating that new additives placed in infant formula are seriously endangering the health of some formula-fed newborns and toddlers.

The report, 'Replacing Mother--Imitating Human Breast Milk in the Laboratory,' details research questioning the alleged benefits of adding "novel" omega-3 fatty acids, produced in laboratories and extracted from algae and fungus, into infant formulas. The additives raised health and safety red flags during preapproval testing while aggressive marketing campaigns by some infant formula manufacturers appear to have encouraged new mothers to give up nursing for the questionable products.

"When I worked in the hospital's neonatal ward, the nurses all called it 'the diarrhea formula'," says Sam Heather Doak, LPN, IBCLC, from Marietta, Ohio. "We've seen infants, tiny little humans, with diarrhea that just wouldn't stop after being given this formula." For infants, virulent and long-term diarrhea is considered a serious and life-threatening event.

The infant formula referenced by Doak was supplemented with Martek Biosciences Corporation's laboratory-produced oils containing DHA and ARA. DHA, an omega-3 fatty acid, and ARA, an omega-6 fatty acid, are naturally found in human breast milk and are considered important nutrients for infants.

But laboratory-produced DHASCO and ARASCO (Martek's names for their proprietary oils) are materially different from the fats found in a mother's breast milk. Martek's products are extracted from fermented algae and fungus, with the use of the neurotoxic solvent hexane. They contain only 40 to 50% DHA and ARA, with the balance from sunflower oil and other components, including some not found in human breast milk and never before a part of the human infant diet.

"It's true that DHA and ARA are important nutrients for developing infants--that's why they're found in human breast milk. But we have also seen that some infants are experiencing side effects like diarrhea from consuming the manufactured DHA and ARA oils in formula," says Jimi Francis, Ph.D., a biochemist specializing in DHA in infant nutrition at the Allie M. Lee Laboratory for Omega-3 Research at the University of Nevada at Reno. Also, humans produce DHA and ARA on their own from other fats.

The Cornucopia Institute, a Wisconsin-based farm and food policy research group and corporate watchdog, presented its report, in partnership with the National Alliance for Breastfeeding Advocacy, to government officials and medical professionals at today's meeting of the U.S. Breastfeeding Committee.

"While infant formula manufacturers claim that these oils are perfectly safe and necessary for proper development, our report provides a more detailed picture," said Charlotte Vallaeys, Farm and Food Policy Analyst with the Cornucopia Institute and lead author of the report. "We investigated how a toxic chemical is used as processing agents in the manufacturing process, the inadequate testing for safety, and most importantly, how some infants are experiencing serious adverse reactions from formula supplemented with these oils," Vallaeys added.

"This report presents a disturbing look at the novel ingredients in infant formula," says Marsha Walker, Executive Director of the National Alliance for Breastfeeding Advocacy. "The FDA has received scores of adverse reports on effects of these ingredients, but, to date, the public's only access to these is through Cornucopia's Freedom of Information Act request. This report will help alert the health care community and federal agencies."

Cornucopia and the National Alliance for Breastfeeding Advocacy are now petitioning the FDA for a warning label alerting parents of the range of possible complications from DHA/ARA-supplemented formula.

For more, visit Cornucopia's website at http://www.cornucopia.org.


'/>"/>
SOURCE The Cornucopia Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
2. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
7. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Datos Health , developer of a pioneering Patient-Generated ... the largest Electronic Medical Records (EMR) provider in South Africa. By using Datos’ ... patient’s remote health progress, empowering the patient to take direct responsibility for their cost ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Miami native and ... a dentist. , “I could have never imagined back in 1991 that this journey ... Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant dentistry ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
Breaking Medicine News(10 mins):